Skip to Content

EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top